Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305356 | 1.00 | NPC1 (0.51) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20744292 | 0.90 | NPC1 (0.51) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20744253 | 0.82 | JAK2 (0.43) | NPC1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2723186 | 0.82 | HRH3 (0.50) | NPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2724949 | 0.81 | HRH3 (0.48) | JAK2JAK1HPGDHSD17B10KDM4E | |
| SCHEMBL2221749 | 0.79 | HSD11B1 (0.47) | HPGDHSD17B10CYP3A4CYP2C9HSD11B1 | |
| SCHEMBL27666940 | 0.78 | HSD11B1 (0.46) | HPGDHSD17B10KDM4ECYP3A4CYP2C9 | |
| SCHEMBL18711309 | 0.78 | ALDH1A1 (0.57) | HPGDHSD17B10CYP3A4CYP2C9HSD11B1 | |
| SCHEMBL27666948 | 0.78 | TRPV1 (0.45) | HSD17B10KDM4ECYP3A4HSD11B1SPR | |
| SCHEMBL20743823 | 0.77 | MEN1 (0.52) | NPC1NAMPTCYP3A4CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | claimed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | claimed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | claimed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | claimed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| EP-3668853-B1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-09-29 | — | — | EP | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| US-20200253967-A1 | NOVEL COMPOUNDS | BioVersys AG (CH) | 2020-08-13 | — | — | US | disclosed |
| EP-3668853-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-111225910-A | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034701-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | NPC1 88/4885PSEN1 2688/4885PSEN2 3190/4885 |
| US-20200253967-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | NPC1 88/4885PSEN1 2688/4885PSEN2 3190/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | NPC1 114/4885PSEN1 1986/4885PSEN2 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.